Custirsen (OGX-011): a second-generation antisense inhibitor of clusterin in development for the treatment of prostate cancer.
Future Oncol
; 8(10): 1239-51, 2012 Oct.
Article
in En
| MEDLINE
| ID: mdl-23130925
ABSTRACT
Clusterin is a stress-induced cytoprotective chaperone that confers broad-spectrum treatment resistance and is overexpressed across a number of cancers. custirsen (OGX-011) is a promising novel second-generation antisense inhibitor of clusterin in clinical development. This article describes the mechanism of action and safety profile of OGX-011 and details the Phase I and II results in human solid organ malignancies. Two Phase III registration trials are currently under recruitment evaluating OGX-011 in combination with chemotherapy in patients with metastatic castration-resistant prostate cancer. These studies not only have the potential to significantly alter the standard of care in prostate cancer, but would also endorse a new class of targets and targeted therapy approach for cancer.
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Prostatic Neoplasms
/
Thionucleotides
/
Oligonucleotides, Antisense
/
Clusterin
Limits:
Humans
/
Male
Country/Region as subject:
America do norte
Language:
En
Journal:
Future Oncol
Year:
2012
Document type:
Article